Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT05921994
- Record updated
- 20 July 2026
- Original description
The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.Read full original descriptionShow less
Long Term observAtional, Prospective, Multicenter Study to Collect iN a Real-world populatIon Data on the treatMent Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) (ANIMA)
The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.
Inclusion: Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:; Patients who provide written informed consent to participate in the study; Male and female patients with ≥18 years of age; Diagnosis of clinically unequivocal moderate to severe HS; Patients for whom a therapy with secukinumab is medically indicated; Documented decision for treatment with marketed secukinumab regardless of this noninterventional study; Treatment with secukinumab according to the latest version of SmPC; Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit.
Exclusion: Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC; Previous exposure to IL-17 inhibitors; For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors; Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation; Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:; Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab.